ArticleCancer medicine2025
CTHRC1 Derived From Cancer-Associated Fibroblasts Promotes Pancreatic Cancer Progression and Metastasis via the LIF-STAT3 Pathway.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- An epithelial mesenchymal transition associated gene signature stratifies risk of ulcerative colitis associated colorectal cancer.Discover oncology · 2026Article
- A novel signature of palmitoylation for predicting prognosis and therapeutic response of hepatocellular carcinoma.Discover oncology · 2026Article
- CTHRC1 Derived From Cancer-Associated Fibroblasts Promotes Pancreatic Cancer Progression and Metastasis via the LIF-STAT3 Pathway.Cancer medicine · 2025Article
- A Sequential Proteomic Relay Defines a Decade-long Pre-diagnostic Window for Pancreatic Cancer.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundCollagen triple helix repeat containing 1 (CTHRC1) is a secreted protein involved in tissue remodeling and fibrotic processes, which also suggests emerging roles in cancer. Studies have shown that it is mainly expressed in the outer membrane fibroblasts of injured arteries and in the neointimal smooth muscle cells, where it promotes cell migration and tissue damage repair. However, the regulatory role of CTHRC1 as a tumor microenvironment factor in pancreatic cancer is not well understood.
methodsWe employed multi-omics analysis combined with cellular and animal experiments to examine the association between CTHRC1 and the LIF/STAT3 pathway in pancreatic cancer clinical specimens. Using AsPC-1/PANC-1 and other cell lines, we conducted proliferation, migration, invasion, and signaling pathway studies, and elucidated the regulatory mechanism of CTHRC1 through genetic interventions and STAT3 inhibitors.
resultsIn this study, we found that CTHRC1 is highly expressed in the cancer-associated fibroblasts (CAFs) of pancreatic cancer and is associated with poor prognosis in patients. Functionally, we observed that CTHRC1 in CAFs promotes the proliferation, migration, and invasion of pancreatic cancer cells both in vitro and in vivo. In mechanistic studies, RNA sequencing revealed that CTHRC1 promotes the proliferation and migration of pancreatic cancer cells through the LIF-mediated STAT3 axis.
conclusionThese findings reveal the role of CTHRC1 in CAFs in pancreatic cancer, suggesting that it is an attractive therapeutic target and tumor marker. This study uncovers the biological mechanism of CTHRC1 in CAFs in pancreatic cancer, providing new strategies for the treatment of pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.